Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656932 | 0.81 | CYP2A6 (0.44) | CYP2A6TDP1HSD17B10HPGDALDH1A1 | |
| SCHEMBL14697329 | 0.77 | KDM4E (0.47) | CYP2A6TDP1HSD17B10HPGDALDH1A1 | |
| SCHEMBL9808744 | 0.75 | HPGD (0.50) | CYP2A6TDP1HSD17B10HPGDALDH1A1 | |
| SCHEMBL30175364 | 0.75 | HPGD (0.50) | CYP2A6TDP1HSD17B10HPGDALDH1A1 | |
| SCHEMBL5057117 | 0.74 | CYP2A6 (0.53) | CYP2A6TDP1HSD17B10HPGDALDH1A1 | |
| SCHEMBL2855183 | 0.69 | CYP2A6 (0.64) | CYP2A6TDP1HSD17B10HPGDALDH1A1 | |
| SCHEMBL9036959 | 0.69 | LOXL2 (0.44) | CYP2A6TDP1HSD17B10HPGDALDH1A1 | |
| SCHEMBL562260 | 0.69 | FLT3 (0.48) | CYP2A6TDP1HSD17B10HPGDKDM4E | |
| SCHEMBL1259018 | 0.67 | FLT3 (0.55) | HPGDALDH1A1KDM4EFLT3CYP1A2 | |
| SCHEMBL329952 | 0.66 | KDM4E (0.48) | CYP2A6TDP1HSD17B10HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11890382-B2 | Edible plant-derived microvesicle compositions for diagnosis and treatment of disease | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230176038-A1 | Methods for Identifying Modulators of Insect Transient Receptor Potential Channels | BASF CORP (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230149316-A1 | EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISEASE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| EP-3311172-B1 | METHODS FOR IDENTIFYING COMPOUNDS THAT DIRECTLY BIND TO INSECT TRANSIENT RECEPTOR POTENTIAL CHANNELS | BASF SE (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-3087391-B1 | METHODS FOR DETERMINING MODULATORS OF INSECT TRANSIENT RECEPTOR POTENTIAL V (TRPV) CHANNEL | BASF SE (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-3735982-A1 | TARGETING GDF6 AND BMP SIGNALING FOR ANTI-MELANOMA THERAPY | The University of Massachusetts (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20200246438-A1 | TARGETING GDF6 AND BMP SIGNALING FOR ANTI-MELANOMA THERAPY | UNIV MASSACHUSETTS (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200188311-A1 | EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISEASE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| EP-3268025-B1 | TARGETING GDF6 AND BMP SIGNALING FOR ANTI-MELANOMA THERAPY | UNIV MASSACHUSETTS (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20180220653-A1 | Methods for Identifying Compounds that Directly Bind to Insect Transient Receptor Potential Channels | BASF SE (DE) | 2018-08-09 | — | — | US | disclosed |
| WO-2003004604-A9 | PHAGE DISPLAYED PDZ DOMAIN LIGANDS | GENENTECH INC (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004003554-A1 | A METHOD FOR THE DETECTION OF APOPTOSIS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20030235611-A1 | Direct cellular energy delivery system | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-25 | — | — | US | disclosed |
| WO-2003096973-A2 | A DIRECT CELLULAR ENERGY DELIVERY SYSTEM | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003097792-A2 | POLYPEPTIDE IMMOBILIZATION | THE UNIVERSITY OF CHICAGO (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003086174-A2 | A NEW METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF MALIGNANT DISEASES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030194754-A1 | Method for the diagnosis and prognosis of malignant diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-16 | — | — | US | disclosed |
| US-20030148264-A1 | Phage displayed PDZ domain ligands | GENENTECH, INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030119054-A1 | Polypeptide immobilization | NATIONAL SCIENCE FOUNDATION | 2003-06-26 | — | — | US | disclosed |
| WO-2003004604-A2 | PHAGE DISPLAYED PDZ DOMAIN LIGANDS | GENENTECH, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148264-A1 | Phage displayed PDZ domain ligands | PDLIM5, CD2BP2, GOPC | CYP2A6 4814/4885TDP1 1941/4885HSD17B10 4024/4885 |
| US-20030119054-A1 | Polypeptide immobilization | SURF4, QPCTL, QPCT | CYP2A6 2505/4885TDP1 1446/4885HSD17B10 2543/4885 |
| US-20030235611-A1 | Direct cellular energy delivery system | NSF, MTREX, SLC25A6 | CYP2A6 3741/4885TDP1 1758/4885HSD17B10 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.